Shares of Belgian biotech Galapagos (GLPG) have dipped considerably in the past couple months along with general weakness in the biotech sector, potentially offering would-be investors an entry point into the stock. Even after recent price action the stock has still increased by over 50% since my original recommendation in 2016 calling the firm 篓a long term buy in biotech篓.
GLPG data by YCharts
In my August update piece readers were reminded of several bullish drivers going forward:
The company has potentially lucrative partnerships with Gilead (NASDAQ:GILD) and AbbVie (NYSE:ABBV). For the first of these involving key asset filgotinib, they received $300 million upfront in cash, a 15% equity investment stake valued at $425 million, milestone payments of up to $1.3 billion down the road, tiered royalties from 20% on upward and a 50/50 profit split in co-promoting territories. Promising data had already been demonstrated in Crohn麓s disease, with results published in The Lancet from the FITZROY study revealing in the intention to treat population that 47% of patients (60 of 128) treated with 200mg of filgotinib achieved clinical remission at week 10, versus 23% of patients in a smaller placebo group (n=44). An ambitious pivotal program was initiated after. The companies moved forward with an ambitious pivotal program in rheumatoid arthritis consisting of three separate studies, from which I inferred significant conviction on their assessment of the drug candidate麓s clinical and commercial potential. I highlighted an asset that while unproven is addressing a large market opportunity expected to grow to $2.4 billion by 2022. Initial results for GLPG1690 in IPF showed that the drug candidate could potentially be a gamechanger, as patients who received it showed an FVC increase of 8 mL as contrasted to other IPF drugs which merely slow the decline. Caveats here included the need to follow up for a longer period of time and the low number of patients treated.
In mid-November the company announced promising top-line results from their mid-stage ALBATROSS trial in cystic fibrosis patients evaluating C1 corrector GLPG2222. When GLPG2222 was combined with Kalydeco data was comparable to that observed with combining tezacaftor with Kalydeco. In the 300mg cohort a dose dependent decrease in sweat chloride concentration (6 mmol/L) was statistically significant, while mean percent predicted FEV1 levels increased by 2.2%.
Top Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)
- [By Ben Levisohn]
Biogen (BIIB) tumbled to the bottom of the S&P 500 today after getting cut by two analysts.
Agence France-Presse/Getty Images
Biogen dropped 4.7% to $278.96 at 4:19 p.m. today, while the S&P 500 declined 0.2% to 2,381.38.
Leerinks Geoffrey Porges cited the “slower than expected ramp for Spinraza” in cutting Biogen to Market Perform from Outperform, while Morgan Stanly’s Matthew Harrison wrote that his decision to cut Biogen to Market Weight from Overweight was “not a downside call, but a timing call.”
Biogen’s market capitalization fell to $60.2 billion today from $63.2 billion yesterday. It reported net income of $3.7 billion on sales of $10.2 billion in 2016.
Barron’s Teresa Rivas recommended buying Biogen in December after the company released positive trial data on its Alzheimer’s drug.
- [By George Budwell]
Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.
- [By WWW.THESTREET.COM]
Breakups have the potential to create a lot of value. Just look at what Biogen (BIIB) did with its hemophilia franchise. Spun out as Bioverativ (BIVV) , shares started trading earlier this year. The stock has climbed some 23% on seemingly no news, Cramer noted.
- [By Todd Campbell]
A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.
Top Biotech Stocks To Own Right Now: ARIAD Pharmaceuticals Inc.(ARIA)
- [By Lisa Levin]
Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).
Top Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Lisa Levin]
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.
- [By Ben Levisohn]
Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.
- [By Chris Dier-Scalise]
On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.
Top Biotech Stocks To Own Right Now: Medivation Inc.(MDVN)
- [By Lisa Levin]
Shares of Medivation Inc (NASDAQ: MDVN) got a boost, shooting up 24 percent to $46.35 amid word of a new report from Bloomberg, saying the company is working with bankers to defend itself against preliminary interest of a takeover. However, Reuters separately reported the company is working with JPMorgan to handle interest from other companies, but said Medivation has no interest in selling itself.
- [By Scott Rubin]
Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.
- [By Ben Levisohn]
Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance, the delta in the average PEG ratio for biotech growth companies (excluding Medivation (MDVN)) compared to non-biotech growth companies is slightly wider than it’s been for most of the year. As such, we remain constructive on the sector. That said, while valuations are attractive on a relative basis, there remains some uncertainty for the group and we would not be surprised to see the volatility continue…